Disease Modifying Antirheumatic Drug

WASHINGTON — In this video, Namrata Singh, MD, MSCI, discusses a presentation from ACR Convergence 2024 that examined patients with rheumatoid arthritis who develop lung cancer.

In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.

Patients with rheumatoid arthritis — either seropositive or seronegative — demonstrate a 1.66-fold higher risk for depression vs. healthy controls, according to data published in JAMA Network Open.

Medicare will begin offering coverage for PrismRA, a molecular diagnostic test that predicts treatment response in certain patients with rheumatoid arthritis, according to a press release from its manufacturer.

Katherine Terracina, MD, assistant professor of rheumatology with McGovern Medical School at UTHealth Houston, spoke with Healio about rheumatoid arthritis in young adults and how early detection from a primary care physician is vital for the best possible treatments.

Female patients with psoriatic arthritis who receive biologic disease-modifying antirheumatic drugs are more likely to have more severe disease and less likely to reach low or minimal disease activity vs. male patients, according to data.

Long-term sarilumab therapy for rheumatoid arthritis demonstrates no new safety outcomes regardless of concurrent use of conventional synthetic disease-modifying antirheumatic drugs, according to data published in Rheumatology.

The COVID-19 pandemic resulted in a rapid adoption of telemedicine among rheumatologists and a delaying of advanced treatments for rheumatoid arthritis, according to data published in Rheumatology Advances in Practice.

Dementia is more common in patients with rheumatoid arthritis who receive conventional synthetic disease modifying anti-rheumatic drugs vs. biologics or targeted synthetic treatments, according to data.